Merus has been granted a patent for a method of treating CLEC12A positive cancer using bispecific antibodies that bind CD3 and CLEC12A. The treatment involves multiple administrations with increasing antibody amounts, starting with a subtherapeutic dose to spare hemopoietic stem cells. GlobalData’s report on Merus gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Merus - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Merus, Personalized cancer vaccines was a key innovation area identified from patents. Merus's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of clec12a positive cancer with bispecific antibody

Source: United States Patent and Trademark Office (USPTO). Credit: Merus NV

A recently granted patent (Publication Number: US11873338B2) discloses a method for treating CLEC12A positive cancer in a subject by administering two or more doses of a bispecific antibody that binds CD3 and CLEC12A. The method involves starting with a subtherapeutic dose in the first administration and gradually increasing the dose in subsequent administrations. The incremental dosing strategy aims to effectively target and treat the cancer while minimizing potential side effects associated with higher initial doses.

Furthermore, the patent also covers a method for purging CLEC12A positive hemopoietic cells from a subject and repopulating the hemopoietic system with normal CLEC12A positive cells. By administering the bispecific antibody in multiple doses, the method aims to eliminate malignant cells while stimulating the regeneration of healthy hemopoietic stem cells and progenitor cells. This approach offers a potential treatment option for conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelofibrosis (MF), or myeloproliferative neoplasm blast phase (MPN-BP) in subjects with CLEC12A positive cancer, providing a hemopoietic stem cell sparing cancer treatment strategy.

To know more about GlobalData’s detailed insights on Merus, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies